Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

MARCH 1, 2023

The Covid-19 pandemic led to massive developments and scientific advances within the field of messenger ribonucleic acid (mRNA) vaccines. Pfizer /BioNTech and Moderna’s mRNA-based vaccines were the first to receive emergency use authorisation (EUA) out of all other Covid-19 vaccines under development in late 2020.

RNA 147

RNA Vaccination Vaccine Genetics 147

Bio Pharma Dive

OCTOBER 6, 2022

A new agreement with the Australian government will bring messenger RNA research and manufacturing capabilities to the country, adding to the COVID-19 vaccine developer’s global expansion efforts.

RNA 200

RNA Manufacturing Vaccination Vaccine 200

BioSpace

APRIL 11, 2021

Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.

Vaccination 142

Vaccination Vaccine RNA Development 142

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

XTalks

MARCH 21, 2022

Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.

RNA 98

RNA Vaccination Vaccine Sales 98

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Scientist Protein 98

Pharmaceutical Technology

APRIL 20, 2023

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Initially reported in 2011, CircRNA is a naturally occurring class of RNA.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

Medical Xpress

DECEMBER 30, 2022

Messenger RNA vaccine technology, once an arcane area of research, became household terminology because of the COVID-19 pandemic, and now scientists are working on an mRNA flu vaccine strategy that, at least in this study, involves a first dose administered as a shot but a booster administered as an mRNA nasal spray.

Vaccination 111

Vaccination Vaccine RNA Scientist 111

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccination 162

Vaccination Vaccine Antibody Development 162

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccination 147

Vaccination Vaccine Development Gene Therapy 147

World of DTC Marketing

APRIL 15, 2021

QUICK READ: Some deaths will occur during the COVID-19 vaccination rollout, but these deaths would have happened for other reasons and are unrelated to the vaccine. In some instances, vaccine-hesitant activists are manufacturing stories of deaths related to the vaccine that never happened.

Vaccination 203

Vaccination Vaccine Manufacturing Development 203

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These viruses carry the genetic information to synthesise an RNA-dependent RNA polymerase.

RNA 240

RNA Genetics Vaccination Vaccine 240

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccination 52

STAT News

OCTOBER 21, 2022

Thirty years ago, Katalin Karikó had what was then an outlandish idea: use messenger RNA as a medicine. One rejection she might now be able to laugh about was a research opportunity with funding for six scientists. But getting funding to demonstrate that might be possible was impossible, despite three decades of trying.

Research 98

Research RNA Scientist Vaccination 98

XTalks

MAY 5, 2023

This week, the US Food and Drug Administration (FDA) approved the world’s first respiratory syncytial virus (RSV) vaccine. GSK says the RSV vaccine will be available for older adults before this year’s RSV season, which usually starts before the winter months. RSV is a negative-strand RNA virus that was first identified in 1955.

Vaccination 105

Vaccination Vaccine FDA Approval Development 105

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. BENEFITS OF ATTENDING: •Explore how mRNA vaccines have led the way in the response against COVID-19 and key takeaways for the industry. David Lowe, Vice President, Research, Evox Therapeutics.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

pharmaphorum

NOVEMBER 30, 2021

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from Pfizer. His most recent role at Pfizer was chief scientific officer for RNA and viral vaccines, a position he held for more than six years. Phil Dormitzer.

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. and Leila Zegna, director of the Kabuki Syndrome Foundation.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. mRNA’s potential for rapid vaccine delivery.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

XTalks

FEBRUARY 24, 2025

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59

Trials RNA Allergies Drugs 59

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. Used in the COVID-19 vaccines, LNPs have shown a promising track record of protecting the mRNA cargo from degradation. Does it degrade?

Bioassay 130

Bioassay RNA Development Drugs 130

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The power of its real-world application was demonstrated by the resounding success of the mRNA COVID-19 vaccines. percent, according to a report by BCC Research.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

pharmaphorum

APRIL 12, 2021

The coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted in Israel. But among patients who had received two doses of the vaccine, the variant’s prevalence was eight times higher than in unvaccinated people – 5.4% Known as variant B.1.351, versus 0.7%.

Vaccination 83

Vaccination Vaccine RNA Protein 83

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

Roots Analysis

NOVEMBER 6, 2023

RNA-based therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. The below figure presents the distribution of next generation RNA-based therapeutics and RNA-based vaccines, based on type of molecule.

RNA 40

RNA Vaccination Vaccine Clinical Trials 40

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

pharmaphorum

NOVEMBER 17, 2020

Pfizer has begun a pilot delivery programme in the US for its experimental COVID-19 vaccine, as the company seeks to overcome logistical challenges caused by its ultra-cold storage requirements. The vaccine developed in partnership with Germany’s BioNTech has been shown to be 90% effective in clinical trials.

Vaccination 77

Vaccination Vaccine RNA Clinical Trials 77

pharmaphorum

DECEMBER 13, 2021

It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget. The Covid-19 pandemic showed what could be done with resources and collaboration to accelerate the development of vaccines. There are multiple other mRNA vaccines that are being developed.

RNA 105

RNA Vaccination Vaccine Development 105

pharmaphorum

NOVEMBER 25, 2020

AstraZeneca’s research chief has said that the more effective dosing regimen of its coronavirus vaccine was discovered by accident. According to Reuters , the AstraZeneca development team made a minor mistake that made them realise they could significantly boost the success rate of the vaccine, codenamed AZD1222.

Vaccination 119

Vaccination Vaccine Bacteria RNA 119

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “But it may be; and if it doesn’t other novel vaccines with similar benefits may well take on this role.”

Protein 126

Protein Vaccination Vaccine Immune Response 126

pharmaphorum

MARCH 11, 2022

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.

Vaccination 81

Vaccination Vaccine Development Manufacturing 81